The role of disposable inhalers in pulmonary drug delivery

Expert Opinion on Drug Delivery

Volumn 12, Issue 1, 2015, Pages 143-157

  De Boer, Anne H ^a   Hagedoorn, Paul ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Disposable; Dry powder inhaler; Inhalation; Nebuliser; Single dose; Single use

Indexed keywords

ANTIBIOTIC AGENT; BRONCHOCONSTRICTING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; INFLUENZA VACCINE; SUBUNIT VACCINE; DRUG; VACCINE;

ASTHMA; AVIAN INFLUENZA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISPOSABLE EQUIPMENT; DISPOSABLE INHALER; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MEGADOSE; DRY POWDER INHALER; EQUIPMENT DESIGN; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INHALATION TEST; INHALER; LOCAL THERAPY; MEDICAL NEBULIZER; METERED DOSE INHALER; PANDEMIC; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SYSTEMIC THERAPY; VACCINATION; ANIMAL; DEVICES; INHALATIONAL DRUG ADMINISTRATION; LUNG DISEASES; MEDICINAL CHEMISTRY; NEBULIZER;

ADMINISTRATION, INHALATION; ANIMALS; BRONCHIAL PROVOCATION TESTS; CHEMISTRY, PHARMACEUTICAL; DISPOSABLE EQUIPMENT; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; LUNG DISEASES; NEBULIZERS AND VAPORIZERS; PHARMACEUTICAL PREPARATIONS; VACCINES;

EID: 84919432640     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.952626     Document Type: Review

References (98)

1. Virchow JC, Crompton GK, Dal Negro R, et al. Importance of inhaler devices in the. management of airway disease. Respir Med 2008;102(1):10-19
2. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994;7:49-75
3. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part 1: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588-99
4. Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cystic Fibros 2009;8:295-315.
5. Mogayzel PJ, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680-9
6. Kollef MH, Hamilton CW, Montgomery AB. Aerosolized antibiotics: do they add to the treatment of pneumonia? Curr Opin Infect Dis 2013;26(6):538-44
7. Kuiper L, Ruijgrok EJ. A review on the clinical use of inhaled amphothericin B. J Aerosol Med Pulm Drug Deliv 2009;22(3):213-17
8. Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc 2014;11(3):425-34
9. Friebel C, Steckel H. Single-use disposable dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2010;7(12):1359-72.
10. Depreter F, Pilcer G, Amighi K. Inhaled proteins: challenges and perspectives. Int J Pharm 2013;447(1-2):251-80
11. Aronson R, Gibney MA, Oza K, et al. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. Clin Ther 2013;35(7):923-33
12. Wicker S, Stirn AV, Rabenau HF, et al. Needlestick injuries: causes, preventability and psychiological impact. Infection 2014;42(3):549-52
13. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005;5(12):905-16
14. Thipphawong JB, Babul N, Morishige RJ, et al. Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery. Anesthesiology 2003;99(3):693-700
15. Riley A, Main M, Morgan F. Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety findings. J Sex Med 2010;7:1508-17
16. Slifka MK, Amanna I. How advances in immunology provide insight into improving vaccine efficacy. Vaccine 2014;32(25):2948-57
17. Ho SL, Coates AL. Effect of dead volume on the efficiency and the cost to deliver medications in cystic fibrosis with four disposable nebulizers. Can Respir J 1999;6(3):253-60
18. Clancy K. Cross-infection and the use and decontamination of placebo inhalers. Br J Nurs 2003;12(13):778-83
19. Blau H, Moussaffi H, Zahav MM, et al. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev 2007;33:491-5
20. Knoch M, Keller M. The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliv 2005;2(2):377-90
21. Lipworth BJ, Sims EJ, Taylor K, et al. Dose-response to salbutamol via a novel palm sized nebuliser (Aerodose Inhaler), conventional nebulizer (Pari LC Plus) and metered dose inhaler (Ventolin Evohaler) in moderate to severe asthmatics. Br J Clin Pharmacol 2005;59(1):5-13
22. Denyer J, Dyche T. The adaptive aerosol delivery (AAD) technology: past, present, and the future. J Aerosol Med Pulm Drug Deliv 2010;23(S1):S1-10
23. Dhand R. Intelligent nebulizers in the age of the internet. The I-neb adaptive aerosol delivery (AAD) system. J Aerosol Med Pulm Drug Deliv 2010;23(S1):3-5
24. Dalby RN, Eicher J, Zierenberg B. Development of respimat soft mist inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl) 2011;4:145-55
25. Dinh K, Myers DJ, Glazer M, et al. In vitro aerosol characterization of Staccato Loxapine. Int J Pharm 2011;403:101-8
26. Lavorini F, Ninane V, Haughney J, et al. Switching from branded to generic inhaled medications: potential impact on asthma and COPD. Expert Opin Drug Deliv 2013;10(12):1597-602
27. Willemse BW, Toelle BG, Li JS, et al. Use of a disposable cup as spacer is effective for the first-aid management of asthma. Respir Med 2003;97(1):86-9
28. Selroos O, Borgstrom L, Ingelf J. Use of dry powder inhalers in acute exacerbations of asthma and COPD. Ther Adv Respir Dis 2009;3(2):81-91
29. Selroos O. Dry-powder inhalers in acute asthma. Ther Deliv 2014;5(1):69-81
30. Brannan JD, Anderson SD, Perry CP, et al. The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline. Respir Res 2005;6:144
31. Lexmond AJ, Hagedoorn P, Frijlink HW, de Boer AH. Challenging the two-minute tidal breathing challenge test. J Aerosol Med Pulm Drug Deliv 2013;26:1-7
32. Lexmond AJ, van der Wiel E, Hagedoorn P, et al. Adenosine dry powder inhalation for bronchial challenge testing, part 2: proof of concept in asthmatic subjects. Eur J Pharm Biopharm 2014. [Epub ahead of print]
33. Colombo G, Terzano C, Colombo P, et al. Metacholine dry powder inhaler as a new tool for bronchial challenge test. Int J Pharm 2008;352(1-2):165-71
34. Rottier BL, van Erp CLP, Sluyter TS, et al. Changes in performance of the pari eflow rapid and pari LC plus during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv 2009;22(3):263-9
35. Ghazanfari T, Elhissi AM, Ding Z, Taylor KM. The influence of fluid physicochemical properties on vibratingmesh nebulization. Int J Pharm 2007;339(1-2):103-11
36. Newhouse MT, Hirst PH, Sarma P, et al. Inhalation of a dry powder tobramycin pulmosphere formulation in healthy volunteers. Chest 2003;124:360-6.
37. Schuster A, Haliburn C, Doring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013;68(4):344-50
38. Vandevanter DR, Geller DE. Tobramycin administered by the TOBI Podhaler for persons with cystic fibrosis: a review. Med Devices (Auckl) 2011;4:179-88
39. Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur J Pharm Biopharm 2014;86:23-30.
40. Aziz MA. Anti-tuberculosis drug resistance in the world. World Health Organization, Geneva; 2004. p. 3
41. Muttil P, Wang C, Hickey AJ. Inhaled Drug Delivery for Tuberculosis Therapy. Pharm Res 2009;26(11):2401-16
42. Traini D, Young PM. Delivery of antibiotics to the respiratory tract: an update. Expert Opin Drug Deliv 2009;6(9):897-905
43. Goldman JM, Bayston SM, OConnor S, Meigh RE. Inhaled micronised gentamicin powder: a new delivery system. Thorax 1990;45:939-40
44. Aquino RP, Prota L, Auriemma G, et al. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. Int J Pharm 2012;426(1-2):100-7
45. Stass H, Nagelschmitz J, Willmann S, et al. Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study. Clin Drug Investig 2013;33(6):419-27
46. Stass H, Weimann B, Nagelschmitz J, et al. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase 1, randomized, doseescalation study. Clin Ther 2013;35(10):1571-81
47. Schoubben A, Giovagnoli S, Tiralti MC, et al. Capreomycin inhalable powders prepared with an innovative spray-drying technique. Int J Pharm 2014;469(1):132-9
48. Duan J, Vogt FG, Li X, et al. Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. Int J Nanomedicine 2013;8:3489-505
49. Lu D, Hickey AJ. Pulmonary vaccine delivery. Expert Rev Vaccines 2007;6(2):213-16
50. Tonnis WF, Kersten GF, Frijlink HW, et al. Pulmonary vaccine delivery: a realistic approach? J Aerosol Med Pulm Drug Deliv 2012;25(5):1-12
51. Pilette C, Ouadrhiri Y, Godding V, et al. Lung mucosal immunity: immunoglobulin-A revisited. Eur Respir J 2001;18:571-88
52. Liu J. Intradermal needle-free powdered drug injection. Thesis; Massachusetts Institute of Technology. 2012. Available from: http://dspace.mit.edu/handle/ 1721.1/74993 [Accessed May 2014]
53. Saluja V, Amorij J-P, Kapteyn JC, et al. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. J Control Release 2010;144:127-33
54. Shah SP, Misra A. Development of liposomal ampherotericin B dry powder inhaler formulation. Drug Deliv 2004;11(4):247-53
55. Singh DJ, Lohade AA, Parmar JJ, et al. Development of chitosan-based dry powder inhalation system of cisplatin for lung cancer. Indian J Pharm Sci 2012;74(6):521-6
56. Zaragoulidis P, Giraleli G, Karamanos NK. Inhaled chemotherapy in lung cancer: safety concerns of nanocomplexes delivered. Ther Deliv 2012;3(9):1021-3
57. Zijlstra GS, Rijkeboer M, van Drooge DJ, et al. Characterization of a cyclosporine A solid dispersion for inhalation. AAPS J 2007;9(2):E190-9
58. Zijlstra GS, Wolting J, Prop J, et al. The efficacy of a new pulmonary cyclosporine A powder formulation in the prevention of transplant rejection in rats. J Heart Lung Transplant 2009;28(5):486-92
59. Mosgoeller W, Prassl R, Zimmer A. Nanoparticle-mediated treatment of pumonary arterial hypertension. Methods Enzymol 2012;508:325-54
60. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through thelungs. Nat Rev Drug Discov 2007;6:67-74.
61. Patton JS, McCabe JG, Hansen SE, Daugherty AL. Absorption of human growth hormone from the rat lung. Biotechnol Ther 1989:1:213-28
62. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996;19:3-36
63. Patton JS, Fishburn CS, Weers JG. The lungs as portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004;1:338-44
64. Bitonti AJ, Dumont JA, Low SC, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci USA 2004;101(26):9763-8
65. Codrons V, Vanderbist F, Ucakar B, et al. Impact of formulation and methods of pulmonary delivery via absorption of parathyroid hormone (1-34) from rat lungs. J Pharm Sci 2004;93:1241-52
66. Patton JS, Nagarajan S, Clark A. Pulmonary absorption and methabolism of peptides and proteins. Respir Drug Deliv 1998;VI(1):17-24
67. Byron PR, Sakagami M, Rypacek F. New pulmonary biopharmaceutics: rate determining absorption and macromolecular transporters. Respir Drug Delivery VII 2000;1:41-8
68. Afrezza a first in class ultra rapid-acting insulin. Available from: www. mannkindcorp.com/product-pipelinediabetes. afrezza.htm [Accessed May 2014]
69. Keating GM. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder of schizophrenia. CNS Drugs 2013;27(6):479-89
70. Civitas therapeutics announces positive Phase 2b results for CVT-301 inhaled levodopa for the treatment of parkinsons disease. 2014. Available from: www. civitastherapeutics.com/cms/sites/default/ files/news/CivitasPhase2bResultsRelease FINAL140428.pdf [Accessed May 2014]
71. Kemp L, Haughney J, Barnes N, et al. Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: a real world observational study. Clinicoecon Outcomes Res 2010;2:75-85
72. Tappenden P, Harnan S, Uttley L, et al. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis. Pharmacoeconomics 2014;32(2):159-72.
73. TOBI, product information 1-800-Chiron8 (244-7668), 2003
74. Fine JM, Whitham ME. Single dose metered dose inhaler for delivery of vaccines and other drugs. US19935215079; 1993
75. OMalley CA, VandenBranden SL, Zheng XT, et al. A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting. Respir Care 2007;52(3):258-62
76. Vecellio L, Abdelrahim ME, Montharu J, et al. Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin. J Cystic Fibros 2011;10:86-92
77. de Boer AH, Hagedoorn P, Westerman EM, et al. Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses. Eur J Pharm Sci 2006;28:171-8
78. Dellamary LA, Tarara TE, Smith DJ, et al. Hollow porous particles in metered dose inhalers. Pharm Res 2000;17:168-74
79. Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH. Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014. Available from: http:// dx.doi.org/10.1016/j.addr.2014.04.004
80. Richardson PC, Boss AH. Technosphere insulin technology. Diabetes Technol Ther 2007;9(Suppl 1):S65-72
81. Young PM, Crapper J, Philips G, et al. Overcoming dose limitations using the Orbital- multi-breath dry powder inhaler. J Aerosol Med Pulm Drug Deliv 2014;27:138-47.
82. Young PM, Salama RO, Zhu B, et al. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis. 2014. Available from: http:// informahealthcare.com/ddi
83. Lexmond AJ, Kruizinga TJ, Hagedoorn P, et al. Effect of inhaler design variables on pediatric use of dry powder inhalers. PLoS One 2014. [Epub ahead of print]
84. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014;311(16):1670-83
85. Cerasa A, Fasano A, Norgante F, et al. Maladaptive pasticity in levodopa-induced dyskineasias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology. Front Neurol 2014;5(49):1-5
86. Pietracupa S, Latorre A, Berardelli A, Fabbrini G. Parkinsonian patients and poor awareness of dyskinesias. Front Neurol 2014;5:32-3
87. Fuller T, Havers F, Xu C, et al. Identifying areas with a high risk of human infection with the avian influenza A (H7N9) virus in East Asia. J Infect. 2014. Available from: http://dx.doi.org/ 10.1016/j.jinf.2014.03.006
88. Cheng VC, Chan JF, To KK, Yuen KY. Clinical management and infection control of SARS: lessons learned. Antiviral Res 2013;100(2):407-19
89. Milne-Price S, Miazgowicz KL, Munster VJ. The emergence of the Middle East Respiratory Syndrome coronavirus. Pathog Dis 2014;71(2):119-34
90. Guamer J, Zaki SR. Histopathology and immunohistochemistry in the diagnosis of bioterrorism agents. J Histochem Cytochem 2006;54(1):3-11
91. Garcia-Contreras L, Sung JC, Muttil P, et al. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother 2010;54(4):1436-42
92. van Drooge DJ, Hinrichs WL, Dickhoff BH, et al. Spray freeze drying to produce stable Delta(9)- tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation. Eur J Pharm Sci 2005;26(2):231-40
93. Schüle S, Schulz-Fademrecht T, Garidel P, et al. Stabilization of IgG1 in spray-dried powders for inhalation. Eur J Pharm Biopharm 2008;69(3):793-807
94. Audouy SA, van der Schaaf G, Hinrichs WL, et al. Development of a dried whole influenze inactivated virus vaccine for pulmonary immunization. Vaccine 2011;29(26):4345-52
95. Demoly P, Hagedoorn P, de Boer AH, Frijlink HW. The clinical relevance of dry powder inhaler performance for drug delivery. Resp Med. [Epub ahead of print]
96. Rootmensen GN, van Keimpema ARJ, Jansen HM, de Haan RJ. Predictors of Incorrect Inhalation Technique in Patients with Asthma or COPD: a Study Using a Validated Videotaped Scoring Method. J Aerosol Med Pulm Drug Deliv 2010;23:323-8
97. Lin WH, Griffin DE, Rota PA, et al. Successful respiratory immunization with dry powder life-attenuated measles virus vaccine in rhesus macaques. Proc Natl Acad Sci USA 2011;108(7):2987-92
98. DirectHaler Pulmonary and nasal drug delivery. 2006. Available from: www.ondrugdelivery.com publications/ Pulmonary.pdf [Accessed June 2014]